Hydrogel for reducing immune-related adverse events during immunotherapy

Year 2018
Project team Jeremiah Johnson with Sachin Bhagchandani & Farrukh Vohidov
Cancer treatments have adverse immune side effects
Hydrogel-based technology controls delivery of therapies
Augmented efficacy of combination therapeutics

Reducing side effects

Cancer treatments, especially new immunotherapies, but also traditional chemotherapy, have adverse immune side effects. To reduce the side effects of immunotherapy and other cancer treatments, we have developed a hydrogel-based technology that provides controlled intra-tumoral delivery of immunomodulators. This technology will be able to augment the therapeutic efficacy of combination immunotherapies as well as significantly reduce systemic toxicities

Sachin Bhagchandani presents their project at IdeaStream 2020.